阿立哌唑与奋乃静治疗脑血管病所致精神障碍的对照研究

Comparative study on aripiprazole and perphenazine in treatment of mental disorders due to vascular disease

目的比较阿立哌唑与奋乃静治疗脑血管病所致精神障碍的临床疗效和安全性。方法将71例脑血管病所致精神障碍患者随机分为两组,分别采用阿立哌唑和奋乃静治疗6周。采用简明精神病评定量表(BPRS)评定疗效;简明智能状况检查量表(MMSE)评定认知状况;药物不良反应量表(TESS)评定不良反应。结果阿立哌唑与奋乃静治疗脑血管病所致精神障碍的临床疗效无显著性差异。阿立哌唑组MMSE减分率显著低于奋乃静组。阿立哌唑组不良反应较奋乃静组少,其中嗜睡、震颤、视物模糊、便秘以及体重增加的发生率与奋乃静组比较有显著性差异。结论阿立哌唑治疗脑血管病所致精神障碍疗效可靠、安全,且对认知功能影响小。

Objective To study the efficacy and safety of aripiprazole in treatment of mental disorders due to vascular disease and compare with perphenazine as a control. Methods 71 cases with mental disorders due to vascular disease were randomly divided into two groups for 6 weeks. The efficacy were assessed by BPRS, the side effects were assessed by treatment emergent symptom scale（TESS） ,and cognitive function were assessed by MMES. Results There was no significant difference in the clinical efficacy between two groups. The change about score of MMSE was significantly fewer in group that treated with aripiprazole. The side effect in group that treated with aripiprazole were fewer than in group that treated with perphenazine, incidence in lethargy, vision blur, constipation and gain in body weight were significantly fewer. Conclusion Aripiprazole is an effective and safe droug in the treatment of mental disorders due to vascular disease and has little side - effect on cognitive function.